Pulmonary embolism (PE)

Diagnostic and therapeutic approach

Dabigatran (Pradaxa)



150mg twice a day.


  • Known hypersensitivity to dabigatran etexilate or dabigatran or any of the excipients of the preparation. Severe renal impairment (CrCl <30 ml / min).
  • Concomitant treatment with inhibitor of P-gp, such as quinidine, dronedarone, ritonavir, tipranavir, nelfinavir, saquinavir, cyclosporin and tacrolimus, but also systemic treatment with ketoconazole, itraconazole or voriconazole (see "Interactions").
  • Manifestation of bleeding, patients with bleeding diathesis or spontaneous or pharmacological impairment of haemostasis.
  • Organic lesions with risk of clinically significant bleeding, including a history of hemorrhagic stroke in the last 6 months.
  • Liver failure or liver disease can have an impact on survival (liver failure in scores of Child-Pugh A, B and C).
  • Artificial cardiac valves